Industrial Liaison Group:
Tel: +44 (0) 1235 778797
Olanzapine is classed as an antipsychotic drug, commonly used to restore the natural balance of substances found in the brain. It has been used in the treatment of conditions such as schizophrenia and bipolar disorders.
A molecule that has been extensively studied to assess its solubility, dissolution properties, and bioavailability, olanzapine is known to have over 60 polymorphs. All solvated and anhydrous forms known to date contain the same SC0 dimer packing motif.
A team from GSK and UCL used a new screening approach to force crystallisation from a polymer based molecular dispersion of olanzapine using heat. Computer generated predictions were used to identify polymorphs with suitable (stable) thermodynamic properties and allowed determination of the crystal structure.
The team used simultaneous differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) at Diamond to study the heat-induced crystallisation of olanzapine dispersed in polyvinylpyrrolidone (PVP). They discovered a new polymorph (Form IV) that does not use the SC0 motif and which exhibits enhanced dissolution properties over Form I.
Diamond Light Source is the UK's national synchrotron science facility, located at the Harwell Science and Innovation Campus in Oxfordshire.
Copyright © 2022 Diamond Light Source
Diamond Light Source Ltd
Harwell Science & Innovation Campus
Diamond Light Source® and the Diamond logo are registered trademarks of Diamond Light Source Ltd
Registered in England and Wales at Diamond House, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, United Kingdom. Company number: 4375679. VAT number: 287 461 957. Economic Operators Registration and Identification (EORI) number: GB287461957003.